Our Neurology Pipeline
Explore our current clinical-stage projects
Phase 3
Tolebrutinib
BTK inhibitor
Multiple Sclerosis
Being studied for: Non-relapsing secondary progressive MS, Primary progressive MS, Relapsing Multiple Sclerosis
Frexalimab
aCD40L mAb
Multiple Sclerosis
Being studied for: Non-relapsing secondary progressive MS, Relapsing multiple sclerosis
Riliprubart
C1s inhibitor
Neuromuscular
Being studied for: IVIg-treated CIDP, SOC-refractory CIDP
Additional Resources
Resource Library
COMPOUND*
CATEGORY*
KEYWORD*
KEYWORD
*indicates a required field
Results ()
All
Publications
Videos
Posters
Websites
MAT-US-2308934 v5.0-P
Exp. Date: 07/14/2027©2024 Sanofi. All rights reserved.Sanofi is a registered trademark of Sanofi or an affiliate.
Additional Resources
Resource Library
COMPOUND*
CATEGORY*
KEYWORD*
KEYWORD
*indicates a required field
Results ()
All
+
Publications
+
Videos
+
Posters
+
Websites
+
Can’t find what you’re looking for?
Find an MSL near you.
To Top
MAT-US-2308934 v5.0-P
Exp. Date: 07/14/2027©2024 Sanofi. All rights reserved.Sanofi is a registered trademark of Sanofi or an affiliate.